天星医疗（01609）盘中涨超26%，截至发稿，股价上涨16.60%，现报123.60港元，成交额1.80亿港元。
天星医疗发布公告，近期，本公司收到欧盟医疗器械新规（CE MDR）认证证书，为中国第一家全线产品获得CE MDR认证的运动医学厂商。同时，公司多个海外市场产品注册批准。公告称，认证证书及注册证书的取得，标志着本公司更多产品符合欧盟及上述国家的法规要求，有利于本公司进一步拓展欧盟、拉丁美洲、东南亚的海外业务布局，进一步增强本公司在国际市场的竞争力和产品布局。
此前，天星医疗正式纳入港股通标的并获选纳入恒生综合指数。据悉，天星医疗是中国领先的运动医学整体解决方案提供商，专注于运动医学植入物、手术设备及相关耗材的研发、生产与商业化。根据灼识咨询数据，按2024 年销售收入计，天星医疗为中国第四大、国产第一大运动医学植入物及器械供应商，市场份额6.5%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.